Release
Savara to Host Analyst and Investor Webinar on September 30, 2024
The webinar will feature presentations from Savara's management team and the following key opinion leaders:
-
Ali Ataya , M.D., Associate Professor of Medicine,University of Florida ,Division of Pulmonary and Critical Care Medicine -
Bruce Trapnell , M.D., IMPALA-2 International Coordinating Investigator, Professor of Medicine and Pediatrics,University of Cincinnati College of Medicine
To access the webinar with slides please click here or visit the “Events & Presentations” section of Savara's website. To access the call by phone, please use this registration link and you will be provided with dial-in details. A replay of the webinar will be available approximately 24 hours after the conclusion of the call and archived for 90 days under the “Events & Presentations” section of the company's website at www.savarapharma.com.
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution, is a granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923223801/en/
(512) 851-1366
Source: